At the news
? BULLISHIMPACT 7/10 8-K filed Feb 25, 2026 at 07:30 ET
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $104.5 million and $400.0 million respectively, representing 24% and 29% year-over-year growth. The company reduced its net loss from $51.1 million in 2024 to $35.5 million in 2025 despite increased R&D spending, and ended the year with $864.2 million in cash. Management expects moderating revenue growth in 2026 as it awaits key clinical data readouts.
- KIMMTRAK net sales were $104.5 million in Q4 2025 (up 24% YoY) and $400.0 million for full year 2025 (up 29% YoY)
- Net loss improved to $35.5 million in 2025 from $51.1 million in 2024 despite higher R&D expenses
- Cash, cash equivalents and marketable securities totaled $864.2 million as of December 31, 2025
- R&D expenses increased to $274.9 million in 2025 from $222.2 million in 2024 due to autoimmune programs and Phase 3 trials
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access